Shenzhen Salubris Pharmaceuticals (002294.SZ)

Executive Summary

Shenzhen Salubris Pharmaceuticals is a publicly traded Chinese biopharmaceutical company with a diversified portfolio spanning cardiovascular, metabolic, renal, and bone health indications. The company has successfully commercialized several products, including Allisartan Isoproxil for hypertension, and maintains a robust pipeline with multiple Phase 3 assets. Recent developments include the completion of Phase 3 trials for Enarodustat (renal anemia) and SAL003 (hyperlipidemia), positioning Salubris for potential regulatory filings in China. The company also has early-stage assets like SAL0123 (osteoporosis) and SAL067 (diabetes), reflecting a balanced mix of innovation and lifecycle management. With a strong domestic presence and a focus on chronic diseases, Salubris is well-positioned to capture market share in China's growing pharmaceutical market. Financial stability and a history of successful product launches underpin its near-term growth trajectory.

Upcoming Catalysts (preview)

• H2 2026Enarodustat NDA Submission/Approval for Renal Anemia75% success
• Q3 2026SAL003 Phase 3 Data Readout for Hyperlipidemia85% success
• H1 2026SAL0123 Phase 1/2 Interim Results in Osteoporosis50% success